Tasimelteon

Chemical formula: C₁₅H₁₉NO₂  Molecular mass: 245.322 g/mol  PubChem compound: 10220503

Therapeutic indications

Tasimelteon is indicated for:

Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind patients

Population group: only adults (18 years old or older)

Tasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tasimelteon is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: HETLIOZ Hard capsule
Structured Product Labeling (SPL/PLR) 2020: HETLIOZ Capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈